Bicara Therapeutics’ (BCAX) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report published on Thursday,Benzinga reports. The firm currently has a $13.01 target price on the stock.

Several other analysts also recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. HC Wainwright upped their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Stock Down 7.0 %

BCAX stock opened at $12.42 on Thursday. The firm has a fifty day simple moving average of $13.19. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Turn Management LLC acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth $14,324,000. Geode Capital Management LLC acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $1,239,000. Vestal Point Capital LP acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $10,825,000. FMR LLC acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $57,913,000. Finally, Braidwell LP acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at about $42,219,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.